Drug intelligence / Profile preview

RGV-Flu-105

Development stage: Unknown
Lead developer: RNAGene
Modality: Vaccines & Immunotherapeutics

Overview

RGV-Flu-105 is a prophylactic vaccine candidate developed by RNAGENE for the prevention of human influenza. It is currently in the discovery phase and targets infectious and respiratory diseases, specifically influenza in humans. The mechanism of action, specific molecular targets, formulation details, and route of administration have not been disclosed as of the latest available information (March 2025). The drug has not yet entered clinical trials or received regulatory approval[1].

Beyond the preview

Go deeper on RGV-Flu-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGV-Flu-105.

Explore the full profile